Abstract
Background/Aims: Following injury to the liver, liver cells, including Kupffer cells and hepatocytes express inducible nitric oxide synthase (iNOS), followed by the production of excess levels of nitric oxide (NO). NO produced by iNOS has been found to contribute to liver injury. Treatment of primary cultures of rat hepatocytes with the proinflammatory cytokine interleukin (IL)-1β stimulated iNOS expression and NO production. Experiments with this in vitro hepatocyte model of liver injury and with in vivo animal models of liver injury have demonstrated that drugs showing a liver-protective effect in vivo also inhibited the induction of iNOS expression and NO production both in vivo and in vitro. Thus, in this in vitro hepatocyte model, the prevention of iNOS expression and NO production are considered indicators of liver protection.
Results/Conclusion: This review describes a simple in vitro liver injury model, consisting of IL-1β-stimulated cultured hepatocytes, and methods used to analyze the mechanisms of action of drugs that inhibit iNOS expression. This in vitro hepatocyte model may be used to assess the liver-protective effects of pharmaceutical agents, herbal medicines, and certain types of foods.
Keywords: Liver-protective effect, inducible nitric oxide synthase, primary cultured hepatocytes, interleukin-1β, nuclear factor κB, antisense transcription.
Graphical Abstract
Inflammation & Allergy - Drug Targets (Discontinued)
Title:Inducible Nitric Oxide Synthase Expression in Liver Injury: Liver Protective Effects on Primary Rat Hepatocytes
Volume: 14 Issue: 2
Author(s): Masaki Kaibori, Tadayoshi Okumura, Kenji Sato, Mikio Nishizawa and Masanori Kon
Affiliation:
Keywords: Liver-protective effect, inducible nitric oxide synthase, primary cultured hepatocytes, interleukin-1β, nuclear factor κB, antisense transcription.
Abstract: Background/Aims: Following injury to the liver, liver cells, including Kupffer cells and hepatocytes express inducible nitric oxide synthase (iNOS), followed by the production of excess levels of nitric oxide (NO). NO produced by iNOS has been found to contribute to liver injury. Treatment of primary cultures of rat hepatocytes with the proinflammatory cytokine interleukin (IL)-1β stimulated iNOS expression and NO production. Experiments with this in vitro hepatocyte model of liver injury and with in vivo animal models of liver injury have demonstrated that drugs showing a liver-protective effect in vivo also inhibited the induction of iNOS expression and NO production both in vivo and in vitro. Thus, in this in vitro hepatocyte model, the prevention of iNOS expression and NO production are considered indicators of liver protection.
Results/Conclusion: This review describes a simple in vitro liver injury model, consisting of IL-1β-stimulated cultured hepatocytes, and methods used to analyze the mechanisms of action of drugs that inhibit iNOS expression. This in vitro hepatocyte model may be used to assess the liver-protective effects of pharmaceutical agents, herbal medicines, and certain types of foods.
Export Options
About this article
Cite this article as:
Kaibori Masaki, Okumura Tadayoshi, Sato Kenji, Nishizawa Mikio and Kon Masanori, Inducible Nitric Oxide Synthase Expression in Liver Injury: Liver Protective Effects on Primary Rat Hepatocytes, Inflammation & Allergy - Drug Targets (Discontinued) 2015; 14 (2) . https://dx.doi.org/10.2174/1871528114666160330113227
DOI https://dx.doi.org/10.2174/1871528114666160330113227 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology TakoTsubo Cardiomyopathy A Short Review
Current Cardiology Reviews Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Potential of Sulphur-containing Amino Acids in the Prevention of Catecholamine-induced Arrhythmias
Current Medicinal Chemistry Stroke: Molecular Mechanisms and Potential Targets for Treatment
Current Molecular Medicine Aesthetic Cardiology: Adipose-Derived Stem Cells for Myocardial Repair
Current Stem Cell Research & Therapy Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism The Role of the Chemokines in Myocardial Ischemia and Reperfusion
Current Vascular Pharmacology Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry Confocal Laser Scanning Microscope, Raman Microscopy and Western Blotting to Evaluate Inflammatory Response after Myocardial Infarction
Current Vascular Pharmacology “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Coagulopathy as a Therapeutic Target for TRALI: Rationale and Possible Sites of Action
Current Pharmaceutical Design From Anreps Phenomenon to Myocardial Hypertrophy: Role of the Na+/H+ Exchanger
Current Cardiology Reviews